New drug combo shows promise for Tough-to-Treat leukemia in younger patients

NCT ID NCT04269213

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests a chemotherapy drug called CPX-351 in people under 60 with secondary acute myeloid leukemia (AML), a type of leukemia that develops after other blood disorders or cancer treatments. The goal is to see how well the drug can make the cancer disappear or improve blood counts. About 21 participants will receive the treatment, and researchers will track how long any benefits last.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia with multilineage dysplasia therapy related acute myeloid leukemia and myelodysplastic syndrome therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Allegheny Health Network Cancer Institute - West Penn Hospital

    Pittsburgh, Pennsylvania, 15224, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • SUNY Upstate Medical Center

    Syracuse, New York, 13210, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States